Tesamorelin
$FDA-approved GHRH analog for HIV-associated lipodystrophy
Tesamorelin is an approved GHRH analog used to reduce excess visceral abdominal fat in adults with HIV-associated lipodystrophy. It is not simply a generic belly-fat peptide for everyone.
The approved evidence is condition-specific and supported by label data. General obesity, bodybuilding, and longevity uses require separate evidence and risk assessment. Understand that the peptide exposure is short but the endocrine effect is assessed through IGF-1 and visceral-fat outcomes over time. Monitor IGF-1, glucose/A1c, edema, malignancy history, and formulation-specific storage rules.
Classification details
- Tesamorelin is a synthetic analog of human growth-hormone-releasing hormone (GHRH) developed by Theratechnologies.
- It stimulates endogenous production and release of growth hormone from the pituitary.
- It is the only FDA-approved GHRF peptide and the only FDA-approved medication for reducing excess visceral abdominal fat in adults with HIV-associated lipodystrophy.
- New formulation, EGRIFTA WR (tesamorelin F8), FDA-approved March 25, 2025 Theratechnologies received FDA approval for a concentrated F8 formulation of tesamorelin under the trade name EGRIFTA WR.
- EGRIFTA WR is formulation-specific. Bioequivalence-style wording is not a practical interchangeability statement: EGRIFTA WR and EGRIFTA SV are not substitutable and have different doses, vial preparation, reconstitution, storage, and label PK values.
- EGRIFTA WR is replacing EGRIFTA SV in the U.S. market. The two formulations are not substitutable, dosing, vial count per dose, reconstitution protocol, and storage requirements all differ.
- Tesamorelin is a GHRH analog with an FDA-approved product context for HIV-associated lipodystrophy/visceral adipose tissue reduction. It does not belong with generic GH secretagogue wellness protocols.
Tesamorelin acts as a highly specific secretagogue for the pituitary gland:
- GHRH Receptor Agonism: It binds to GHRH receptors on pituitary somatotrophs, stimulating the natural, pulsatile release of endogenous Growth Hormone (GH).
- Lipolysis (Visceral Fat Targeting): Elevated GH acts directly on adipocytes and stimulates the production of IGF-1 in the liver. Clinical data in the approved HIV-lipodystrophy context show reduction of excess visceral adipose tissue (VAT). This is GH/IGF-1-mediated VAT reduction in a specific indication, not a literal “unique affinity” or direct fat-melting effect. Mitochondrial &
- Cognitive Support: Recent research suggests it improves mitochondrial oxidative phosphorylation in muscles and may have neuroprotective effects by reducing brain pro-inflammatory markers.
- It stimulates endogenous GH and IGF-1 through GHRH receptor signaling, leading to VAT reduction in the approved context. It does not directly melt fat independent of the GH/IGF-1 axis.